Liang Jackson J, Muser Daniele, Santangeli Pasquale
Electrophysiology Section, Division of Cardiology, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA.
Electrophysiology Section, Division of Cardiology, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA.
Card Electrophysiol Clin. 2017 Mar;9(1):153-165. doi: 10.1016/j.ccep.2016.10.012. Epub 2016 Dec 24.
Catheter ablation is an increasingly used treatment option for patients with ventricular tachycardia (VT) in the setting of structural heart disease. Although there are extensive data from several retrospective studies as well as prospective nonrandomized observational studies, there are limited data from relatively few randomized controlled trials, especially comparing VT ablation with antiarrhythmic drugs. In this review, the authors aim to summarize the major studies examining efficacy of VT ablation in patients with structural heart disease, discuss barriers to enrollment and completion of randomized clinical trials, and propose areas of future research in the field.
对于患有结构性心脏病的室性心动过速（VT）患者，导管消融是一种越来越常用的治疗选择。尽管有来自多项回顾性研究以及前瞻性非随机观察性研究的大量数据，但相对较少的随机对照试验的数据有限，尤其是比较室性心动过速消融与抗心律失常药物的试验。在这篇综述中，作者旨在总结研究结构性心脏病患者室性心动过速消融疗效的主要研究，讨论随机临床试验入组和完成的障碍，并提出该领域未来的研究方向。
